# A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions

> **NCT00992238** · PHASE1 · COMPLETED · sponsor: **Padagis LLC** · enrollment: 48 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Flavoxate Hydrochloride Tablets, 100mg
- **DRUG:** Urispas® Tablets, 100mg

## Key facts

- **NCT ID:** NCT00992238
- **Lead sponsor:** Padagis LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 48 (—)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992238, "A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00992238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*